ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,842.63
1.12%
Dow Jones
43,006.59
1.14%
US Dollar vs MXN
20.41553
0.05%
Brent Oil
69.615
0.51%
Bitcoin
91,617.47
1.09%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Bicara Therapeutics Inc (BCAX) Cotización

Bicara Therapeutics Inc

Bicara Therapeutics Inc (BCAX)

NASDAQ
14.88
1.21
(8.85%)
Cerrado 05 Marzo 3:00PM
Delayed by 15 minutes
14.88
0.00
(0.00%)
Fuera de horario: 4:36PM
Delayed by 15 minutes
Gráfico avanzado

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
14.88
Postura de Compra
13.06
Postura de Venta
14.88
Volume Operado de la Acción
344,179
12.81 Rango del Día 14.93
11.10 Rango de 52 semanas 28.09
Capitalización de Mercado [m]
809.704M
Precio Anterior
13.67
Precio de Apertura
13.80
Hora
8
@
14.88
Última hora de negociación
Volumen financiero
US$ 4,859,520
Precio Promedio Ponderado
14.1192
Volumen promedio (3 m)
449,472
Acciones en circulación
54,415,619
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-15.58
Beneficio por acción (BPA)
-0.96
turnover
-
Beneficio neto
-51.99M

Acerca de Bicara Therapeutics Inc

Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor... Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Our lead program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. Ficerafusp alfa is initially being developed in head and neck squamous cell carcinoma, or HNSCC, where there remains a significant unmet need. We intend to initiate a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab as a first-line therapy in recurrent/metastatic HNSCC excluding HPV-positive patients with oropharyngeal squamous cell carcinoma late in the fourth quarter of 2024 or early in the first quarter of 2025. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.bicara.com
Sede
Wilmington, Delaware, USA
Fundado
-
Bicara Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BCAX. The last closing price for Bicara Therapeutics was US$13.67. Over the last year, Bicara Therapeutics shares have traded in a share price range of US$ 11.10 to US$ 28.09.

Bicara Therapeutics currently has 54,415,619 shares in issue. The market capitalisation of Bicara Therapeutics is US$743.86 million. Bicara Therapeutics has a price to earnings ratio (PE ratio) of -15.58.

BCAX Últimas noticias

Más noticias

Form 8-K - Current report
Edgar (US Regulatory)
13 Enero 2025
BCAX (8.85%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
12 Noviembre 2024
BCAX (8.85%)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
12.5720.877335499612.3114.8811.76527153312.93969784CS
42.5620.779220779212.3214.8811.6433540112.92396513CS
12-4.64-23.770491803319.5220.708711.144947214.95199043CS
26-11.37-43.314285714326.2528.0911.140998518.48901397CS
52-11.37-43.314285714326.2528.0911.140998518.48901397CS
156-11.37-43.314285714326.2528.0911.140998518.48901397CS
260-11.37-43.314285714326.2528.0911.140998518.48901397CS

BCAX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Bicara Therapeutics?
El precio actual de las acciones de Bicara Therapeutics es US$ 14.88
¿Cuántas acciones de Bicara Therapeutics están en circulación?
Bicara Therapeutics tiene 54,415,619 acciones en circulación
¿Cuál es la capitalización de mercado de Bicara Therapeutics?
La capitalización de mercado de Bicara Therapeutics es USD 743.86M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Bicara Therapeutics?
Bicara Therapeutics ha negociado en un rango de US$ 11.10 a US$ 28.09 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Bicara Therapeutics?
El ratio precio/beneficio de Bicara Therapeutics es -15.58
¿Cuál es la moneda de reporte de Bicara Therapeutics?
Bicara Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Bicara Therapeutics?
El último beneficio anual de Bicara Therapeutics es USD -51.99M
¿Cuál es la dirección registrada de Bicara Therapeutics?
La dirección registrada de Bicara Therapeutics es CORPORATION TRUST CENTER, 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Bicara Therapeutics?
La dirección del sitio web de Bicara Therapeutics es www.bicara.com
¿En qué sector industrial opera Bicara Therapeutics?
Bicara Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
GVVisionary Holdings Inc
US$ 3.6999
(186.81%)
184.57M
CMRXChimerix Inc
US$ 8.435
(70.06%)
117.31M
ARBBARB IOT Group Ltd
US$ 0.8262
(58.88%)
86.46M
CDXCChromaDex Corporation
US$ 8.5507
(52.69%)
18.47M
SOBRSOBR Safe Inc
US$ 0.6602
(41.04%)
10.66M
CUTRCutera Inc
US$ 0.1209
(-61.55%)
23.22M
XCURExicure Inc
US$ 9.92
(-30.53%)
133.38k
STBXStarBox Group Holdings Ltd
US$ 0.3481
(-29.20%)
2.7M
LBGJLi Bang International Corporation Inc
US$ 1.50
(-25.00%)
269.2k
SMSTDefiance Daily Target 2x Short MSTR ETF
US$ 4.7255
(-24.75%)
29.42M
NVDANVIDIA Corporation
US$ 117.30
(1.13%)
278.85M
GVVisionary Holdings Inc
US$ 3.6999
(186.81%)
184.57M
ADTXAditxt Inc
US$ 0.0592
(18.88%)
157.55M
INTCIntel Corporation
US$ 20.81
(-2.44%)
125.38M
CMRXChimerix Inc
US$ 8.435
(70.06%)
117.31M

BCAX Finanzas

Finanzas

Discusión

Ver feed completo
Oleblue Oleblue 4 minutos hace
The chart looks bad with OBV very negative. Who knows where the bottom is?

https://api.wsj.net/api/kaavio/charts/big.chart?nosettings=1&symb=lwlg&uf=32&type=4&size=4&sid=3120061&style=330&freq=1&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=7&rand=2090386408&compidx=aaaaa%3a
LWLG
rosemountbomber rosemountbomber 4 minutos hace
Appreciate the response JRoon. That seems logical to me. If this does indeed happen do you have a guess what will that final take out value be? Right at around where we sit now, or do they have to sweeten it a bit to get it approved?
AMRN
flipper44 flipper44 6 minutos hace
“FeMike and Norisknorewards are two sides on the same coin. Both want to dim any approval announcement by putting otherwise concurrent announcements on either the front end by weeks/months (femike’s desire) or the back end by week/months. NWBO needs to fill in the friggen blanks upon any maa approva
NWBO
Dennis14 Dennis14 6 minutos hace
https://psychedelicinvest.com/red-light-holland-appoints-keith-li-as-chief-financial-officer-and-provides-corporate-updates/
TRIP
930 930 6 minutos hace
Up 5.7%, better than a sharp stick in the eye!
KULR
ChanceVision ChanceVision 6 minutos hace
Hell Yeah! Can't Wait! 🌽🌮🌮🌮🤠👌🏼

Things are really starting to come together.

$AABB
AABB
dalesio_98 dalesio_98 7 minutos hace
IE OUT ... indeed, far out and ultimately delusional. More of the same, it did end years back!

Good luck to All!
norisknorewards norisknorewards 7 minutos hace
Makes no sense to me, show me where I said that..
NWBO
lodas lodas 8 minutos hace
yo ron????......there is NO COURT to adjudicate anything you have said in this post....The chapter 11 court closed 13 years ago with all parties in agreement to the issues....There is no 25 billion in T-Bills somewhere hiding that will return to former shareholders...do you have problems reading of
COOP
HoldEm777 HoldEm777 10 minutos hace
T2 to T4 seems to be a pattern
GTVH
Hardazoak Hardazoak 10 minutos hace
Benny has more smoking hot aabb yellow corn taco factory videos. Are you ready chanceV?
AABB
flipper44 flipper44 11 minutos hace
I stand by what I said.
NWBO
RichieBoy RichieBoy 11 minutos hace
Just think though MTi almost certainly (99.9% sure) are under Exclusivity and Confidentiality clauses (at least) in that BINDING agreement with OMT.

Meaning MTi could already be making kettle drums of CASH and we all would be none the WISER until the acquisition is made public... 
AFFU
Hardazoak Hardazoak 11 minutos hace
Easier question: Take a wild guess of the real identity of Orange Dave.
AABB
alertmeipp alertmeipp 12 minutos hace
We will see. Would be a very different company a year out.
ENTA
Hardazoak Hardazoak 12 minutos hace
Good, simple question, take a wild guess on the true identity of Gitreal of ihub.
AABB
loanranger loanranger 13 minutos hace
If you choose not to believe FINRA's Short Interest Report I can't help you.
There is no significant short interest in RSPI and if there was it would have been covered long ago, when the price fell apart.
RSPI
Cosa Cosa 13 minutos hace
How is this good?

Once TDAPA ends and the drug is incorporated into the bundle without a rate adjustment, facilities may have financial incentives to limit use of costlier new drugs
ARDX
Gerry6 Gerry6 13 minutos hace
Careful...negative posts could affect the share price.
SIRC
NY1972 NY1972 13 minutos hace
Yes. A lot of patients harbor both HCV and HBV. HPV-driven cancers (cervical, throat) have the highest MIC-A/B expression, making them ideal for MIC-A/B-based immunotherapies.
Do you think 525 + Rituximab will be more potent since LD is not used?
FATE
norisknorewards norisknorewards 13 minutos hace
"Both want to dim any approval announcement".....

Umm, no, i didn't say that whatsoever, I gave my theory as to what I think their strategy is.

Why the f would I want to dim an approval announcement?
NWBO
Dennis14 Dennis14 13 minutos hace
https://www.newsfilecorp.com/release/238058/Red-Light-Holland-Appoints-Keith-Li-as-Chief-Financial-Officer-and-Provides-Corporate-Updates As of January 22 2025
TRIP
Oleblue Oleblue 14 minutos hace
The 10 day hourly chart shows that it bottomed at $80 twice and the OBV has turned up as of today.

https://api.wsj.net/api/kaavio/charts/big.chart?nosettings=1&symb=pltr&uf=32&type=4&size=4&sid=206708234&style=330&freq=8&entitlementtoken=0c33378313484ba9b46b8e24ded87dd6&time=18&rand=2
PLTR
100lbStriper 100lbStriper 14 minutos hace
just more drama like the man says. that trial just needs to start on the 18th is my only concern. we need that one under our belt and the rest is a cake walk.
NLST

Su Consulta Reciente

NASDAQ
BCAX
Bicara Therapeutics
TG
WCCA
WT Commodity Securities
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios